Please upgrade your browser.
Stanford University scientists have discovered a single drug that has killed or shrunk every kind of cancer tumor it has been used against — a new anti-cancer weapon that some have described as a kind of medical Holy Grail.
Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases
Cul-7 forms a complex with the adaptor protein SKP1, RBX1, and the receptor protein FBXW8 to constitute an active CRL-7 (Figure 2F), whereas very little is known about other components that may bind to Cul-9/Parc to form an active CRL-916. Cul-7−/− mice die immediately after birth due to respiratory distress.
In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability
The report also finds that surveyed oncologists and managed care organization (MCO) pharmacy directors indicate that improved overall survival and progression-free survival are the greatest unmet needs in pretreated advanced renal cell carcinoma. Interviewed thought leaders are optimistic that Bristol-Myers Squibb's nivolumab has the potential to improve overall survival and at least in part address this unmet need.
On Saturday, the court heard testimony from Health Ministry nutritionist Fathiah Bint Abdullah Al Rashdi who said that the inspected samples contained harmful fungi that could cause liver and kidney cancer, according to a report in Arabic daily Al Watan today (Sunday).
Transforming the practice of medicine, one patient at a time.
CRLX101 is being studied in clinical trials in renal cell carcinoma in combination with Avastin®
March is Kidney Cancer Awareness Month and the Kidney Cancer Association (KCA), with its more than 70,000 members worldwide, are celebrating by honoring the many collaborators who have helped to make ours the largest organization of its kind.
TIVO-1 was the first registrational study in 1st-line RCC to compare an investigational agent against an approved VEGF therapy.
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study presented at the 28th Annual EAU Congress currently on-going in Milan.
|NeonCRM by Neon One|